Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01192204
Other study ID # 2009C0086
Secondary ID RC2CA148099
Status Completed
Phase Phase 1/Phase 2
First received August 30, 2010
Last updated August 12, 2015
Start date October 2010
Est. completion date February 2014

Study information

Verified date November 2013
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a multicenter placebo-controlled clinical trial to assess the effects of a topically applied gel on precancerous oral epithelial lesions. A total of 41 participants will be enrolled in this trial, and 22 of them will be enrolled at Ohio State. [The remaining 19 participants will be enrolled at the University of North Carolina (9 participants) and the University of Louisville (8 participants)]. At all three institutions, half of the participants will randomly be assigned to the 10% FBR gel (0.5 gm four times daily for 3 months), while half will enter the placebo control arm. All trial participants will have a pretreatment (including lesional and perilesional tissue) biopsy taken before and an excisional biopsy after 3 months of treatment. As pretreatment indices are compared to post treatment effects on each patient, patients serve as their own internal control. Pretreatment lesional biopsies are obtained to establish a pretreatment diagnosis and provide a pretreatment baseline for the experimental parameters.


Description:

Read more »
Read more »

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
10% FBR containing bioadhesive gel
0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
placebo gel
0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States The Ohio State University, College of Dentistry Columbus Ohio
United States University of Louisville, School of Dentistry Louisville Kentucky

Sponsors (4)

Lead Sponsor Collaborator
Ohio State University National Cancer Institute (NCI), University of Louisville, University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

References & Publications (41)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment A hemisection of lesional tissue will be conducted before the 3 month treatment to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. Anl excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment to provide a posttreatment diagnosis. The 0 to 8 histologic scale was:0=normal with or without hyperkeratosis BEST OUTCOME, 1=atypia, 2=mild dysplasia, 3=mild-moderate dysplasia, 4=moderate dysplasia,5=moderate-severe dysplasia,6=severe dysplasia, 7=carcinoma in situ, 8=invasive oral squamous cell carcinoma (WORST OUTCOME). Before and after the 3 month treatment. No
Secondary Changes in Lesional Sizes The remaining oral dysplasia lesion will be inspected at each follow up appointment (every 10-14 days). Biopsies will be immediately conducted on patients with any indication of malignant transformation including indurated, rolled borders, nonhealing ulcers, etc. Accordingly, these patients will withdraw from the trial. Participants will also be monitored for any changes consistent with contact mucositis e.g. soreness and erythema at application site. Clinical photographs were taken for the patients records. Pre treatment and post treatment photographs, with a ruler in place, were used for accurate pre and post treatment size measurement. NOTE: if treatment is beneficial, lesional size will decrease which will be reflected as a negative number. pretreatment and posttreatment (3 months treatment duration) No
Secondary Treatment Changes in Loss of Heterozygosity Events Laboratory experiments will be conducted to assess the effects of gel treatment on pre and post loss of heterozygosity (LOH) events at loci associated with tumor suppressor genes. Before and after the 3 month treatment duration No
See also
  Status Clinical Trial Phase
Completed NCT02397252 - Cervical And Self-Sample In Screening Study N/A
Recruiting NCT03195218 - HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) N/A
Recruiting NCT02833363 - Difference of Gastric Microbiota in the Process of Correa's Model. Phase 4
Completed NCT01924117 - Genotypification and Predisposing Factors in Human Papilloma Virus Infection N/A
Recruiting NCT02510027 - Triage Strategies in Cervical Cancer Prevention N/A
Completed NCT01384864 - Endoscopic Multispectral Imaging for the Early Detection of Barrett's Neoplasia Phase 0
Completed NCT00352404 - Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia Phase 3